POST STUDY ACCESS OF CSL312 (GARADACIMAB) FOR THE ROUTINE PREVENTION OF
HAE ATTACKS IN PEDIATRIC PARTICIPANTS (2-11 YEARS OLD) WITH HEREDITARY
ANGIOEDEMA (HAE) WHO HAVE COMPLETED CSL312_3003 STUDY
- Registry ID
- CSL312_5001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- CSL BEHRING
- Start date
- 2026-07-01
- Last update
- 2025-05-13
Conditions
Related clinical trials
- PHASE 3 TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA – ORBIT-EXPANSE
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIRNA TARGETING OF PREKALLIKREIN WITH ADX-324 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA
- PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA ¿ ALPHA-ORBIT
- A PHASE 4 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AFTER SWITCHING
TO CSL312 (GARADACIMAB) FROM CURRENT PROPHYLACTIC HAE
TREATMENT IN SUBJECTS WITH HAE ¿ 12 YEARS OF AGE
- HAELO: A PHASE 3, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NTLA-2002 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA
- A LONG-TERM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED DEUCRICTIBANT EXTENDED-RELEASE TABLET FOR PROPHYLAXIS AGAINST ANGIOEDEMA ATTACKS IN ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA
View on source registry